Top Weekend News Stories November 19 2017

The top news stories this weekend that could impact stocks on the GuerillaStockTrading watch list.
Continue reading “Top Weekend News Stories November 19 2017”

Top News Stories November 16 2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories November 16 2017”

Top News Stories November 14 2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories November 14 2017”

Top News Stories For November 13 2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories For November 13 2017”

Top Weekend News Stories November 11 – 12, 2017

The top news stories this weekend from stocks on the GuerillaStockTrading watch list.
Continue reading “Top Weekend News Stories November 11 – 12, 2017”

Top News Stories November 9 2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories November 9 2017”

Top 5 CAR T Stocks To Add To Your Watch List

CAR T stocks are the buzz right now. Even grocery store workers are talking about the FDA approval of the first CAR-T therapy from Novartis last week. Labiotech wrote about the Novartis CAR T approval here.

As swing traders we can’t chase any of these stocks. Back in July I wrote about going long both Cellectis and Novartis.

Back in February 2017 I linked to this YouTube video on how the National Cancer Institute cured leukemia that you may want to review to gain a fuller understanding of what this disruptive technology is about.

Had you bought Cellectis when I wrote about it back in July, you would be up more than 15% right now.

These stocks just can’t be chased higher right now.

My goal is that GuerillaStockTrading become the smartest stock trading website on the internet for amateur traders. Being smart means NEVER chasing a stock higher.

Most of you that watch the weekly Saturday show on YouTube already know that I made a New Year’s resolution to NEVER chase a stock higher in 2017. After making that resolution, my trading profits have improved by over 1000%.

You have to ask yourself, are you a predator or prey for some other predator? You want to be a predator. If you stalk and wait for a pullback to pounce, you’re a predator. If you chase a stock higher, you’re prey. Make sure to review this stock trading lesson on swing trading and the difference between being a predator or being prey.

CAR T Stocks

Be a smart trader. Instead of chasing, create a CAR T watch list and add these stocks to it:

CAR T Stocks Gilead

The next CART-T FDA approval will likely come from Gilead, which just announced the €10Bn acquisition of Kite Pharma that is currently waiting for an FDA decision on its CAR-T candidate KTE-C19.

GILD does not present an entry opportunity at the moment. Prices have been extended to the upside lately. For a good entry it is better to wait for a consolidation.

CAR T Stocks Novartis

Even though the FDA has approved Novartis’ CAR-T therapy Kymriah, officially blessing a new way to attack cancer, the stock has gone pretty much no where. That’s a cautionary yellow flag to traders who think that just because the FDA has approved a CAR-T therapy treatment that this translates into making money in CAR T stocks. Notice how the large players volume continues to downtrend and the Twiggs Money Flow is negative suggesting the stock is still under distribution. I think Novartis is a better setup for a long entry than Gilead. Prices have been consolidating lately and there is a support zone below the current price at $83.76, a stop order could be placed below this zone.

CAR T Stocks Cellectis

Cellectis is a death-trap stock. This is like the stock you tell your father-in-law to check out because it looks so good (wink, wink). Cellectis stock does NOT present a decent entry opportunity at the moment. Prices have been extended to the upside lately. For a good entry it is better to wait for a consolidation.

CAR T Stocks Juno Therapeutics

JUNO is a little better than CLLS but not by much. JUNO does not present a good swing long entry opportunity at the moment. Price movement has been a little bit too volatile to find a nice entry and exit point. It is probably a good idea to wait for more of a consolidation first.

CAR T Stocks Celyad

Large players have been selling CYAD into the upward move. We see reduced volatility while prices have been consolidating in the most recent period. There is a very little resistance above the current price. I don’t really like trading ADRs when I can find a similar opportunity in a non-ADR stock. The Twiggs Money Flow is weak and the falling large players volume means the stock is not a good setup right now unless both improve. I did this stock trading lesson on large players volume that you should review.

Make sure to leave your comments on CART T stocks and this exciting new medical technology below.

Cellectis CAR T Treatment Will Be Better Than Novartis

The Cellectis CAR T treatment will be better than Novartis on price point. The Novartis therapy called tisagenlecleucel will be very expensive and this is a big problem as insurance companies will simply not cover it. This is why Cellectis stock got a sympathy bump on Friday after Novartis got an FDA Advisory Panel positive recommendation which should result in the first FDA approval of a CAR T treatment.

With Novartis’ method, each patient will require his or her own special batch of genetically engineered cells to be made. The process takes about 22 days and costs around $500,000.

Cellectis CAR T Treatment Can Be Mass Produced

Cellectis just submitted an Investigational New Drug application to the FDA for an off-the-shelf CAR-T candidate. If approved, the company will soon start Phase I trials with UCART123 in patients with acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.

Cellectis is working on a technology it calls universal CAR-T therapy or UCART. Cellectis has edited genes in these cells to make them like universal donor cells. They can work in the vast majority of patients. UCART can be manufactured in large scale using cells from a healthy donor instead of treatments relying on the patient’s own cells. This means that Cellectis can mass-produce a CAR-T therapy, making it cheaper to produce.

Cellectis CAR T Treatment Deals With Cytokine-release Syndrome

Cytokine-release syndrome (CRS) is a big problem for all CAR T treatments. A whopping 79% of trial patients experienced CRS, of which 21% was grade 3 and 27% was grade 4. CRS occurred within 3 days of treatment (range, 1-22) and lasted for a median of 8 days (range, 1-36). Fifty-nine percent of patients with CRS were admitted to the intensive care unit for a median of 8 days (range, 1-34).

Cellectis is working on preventing CRS by controlling the activity of these genetically modified cells. It’s designed an architecture where CAR T cells can be given the equivalent of an on-off switch. The switch can be a small-molecule drug that’s given to the patient to control the activity of the cells. The possibility of controlling CAR T activity is very desirable to mitigate potential unwanted risks such as CRS. To date, few strategies are available and mostly rely on suicide mechanisms that ultimately lead to a complete eradication of the engineered T-cells, thus resulting in a premature end of the treatment.

Cellectis CAR T treatment should not only be cheaper than Novartis’ $500,000 price tag, it should also be safer with the ability to control the immune system response.

Cellectis Fundamentals

CLLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative. CLLS has a Quick Ratio of 5.68. This indicates that CLLS is financially healthy and has no problem in meeting its short term obligations. CLLS has an Altman-Z score of 10.37. This indicates that CLLS is financially healthy and little risk of bankruptcy at the moment.

Like most clinical-stage biopharmaceutical companies, the fundamental data is poor on Cellectis.

Cellectis Stock Chart

Cellectis stock had a big Novartis sympathy move on Friday, July 14, 2017. This is a stock you do not want to chase. The chart looks like a horrible setup right now IMO. Price has spiked to the upside. It is better to buy on a consolidation rather than a spike.

While this stock is not a good buy right now, it’s worth putting on our watch list to stalk for the next consolidation.

Novartis FDA Car T Approval – Most Exciting New Medicine Of Our Lifetimes

Big news: Novartis FDA Car T approval is likely coming soon after a Food and Drug Administration advisory panel unanimously recommended approval for Novartis’s leukemia drug tisagenlecleucel. The FDA usually follows its panels’ recommendations.

The big thing though will be price point. Car T is very expensive because it involves personalized treatment. If it’s too expensive, insurance companies won’t cover it.

Novartis FDA Car T

Novartis said that in patients with recurrent leukemia, 75% were still cancer free after CAR-T treatment.

Wells Fargo’s David Maris told clients that this ground-breaking approval is “the most exciting thing I’ve seen in my lifetime.”

CAR-T medicine is a new, personalized treatment which requires taking a patient’s own cells, removing them from the body, reengineering them for immunotherapy, and placing them back in the body.

The official Novartis FDA Car T approval is expected in October 2017.

Novartis Stock Chart

NVS has an ok setup pattern but I’m not really thrilled about it. I feel like we need more of a consolidation and a candle over candle reversal too so we know other buyers are stepping in at this level. There is a very little resistance above the current price. There is a support zone below the current price at 82.96, a stop order could be placed below this zone.